Adiponectin and colorectal adenomas: Self Defense Forces Health Study

Cancer Science

Volumn 99, Issue 4, 2008, Pages 781-786

  Fukumoto, Jin ^a   Otake, Toshie ^a,b   Tajima, Osamu ^a,c   Tabata, Shinji ^b   Abe, Hiroshi ^b   Mizoue, Tetsuya ^d   Ohnaka, Keizo ^a   Kono, Suminori ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Self Defense Forces Fukuoka Hospital   (Japan)

^c Self Defense Forces Kumamoto Hospital   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN;

ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER RISK; CIGARETTE SMOKING; COLONOSCOPY; COLORECTAL ADENOMA; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; OBESITY; OCCUPATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK FACTOR; TUMOR VOLUME; WAIST CIRCUMFERENCE;

ADENOMA; ADIPONECTIN; COLORECTAL NEOPLASMS; CROSS-SECTIONAL STUDIES; HUMANS; JAPAN; MALE; MOLECULAR WEIGHT;

EID: 41349099849     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00745.x     Document Type: Article

References (35)

1. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-92.
2. Ryo M, Nakamura T, Kihara S et.al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68: 975-81.
3. Nakashima R, Kamei N, Yamane K, Nakanishi S, Nakashima A, Kohno N. Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. J Clin Endocrinol Metab 2006; 91: 3873-7.
4. Hanley AJ, Bowden D, Wagenknecht LE et al. Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endocrinol Metab 2007; 92: 2665-71.
5. Dal Maso L, Augustin LS, Karalis A et al. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004; 89: 1160-3.
6. Petridou E, Mantzoros C, Dessypris N et al. Plasma adiponectin concentrations in relation to endometrial cancer: A case-control study in Greece. J Clin Endocrinol Metab 2003; 88: 993-7.
7. Miyoshi Y, Funahashi T, Kihara S et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003; 9: 5699-704.
8. Mantzoros C, Petridou E, Dessypris N et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004; 89: 1102-7.
9. Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS. Low adiponectin levels are associated with renal cell carcinoma: A case-control study. Int J Cancer 2007; 120: 1573-8.
10. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study. J Natl Cancer Inst 2005; 97: 1688-94.
11. Lukanova A, Söderberg S, Kaaks R, Jellum E, Stattin P. Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 401-2.
12. Otake S, Takeda H, Suzuki Y et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: Evidence for participation of insulin resistance. Clin Cancer Res 2005; 11: 3642-6.
13. Levine JS, Ahnen DJ. Adenomatous polyps of the colon. N Engl J Med 2006; 355: 2551-7.
14. Hara K, Horikoshi M, Yamauchi T et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006; 29: 1357-62.
15. Fisher FF, Trujillo ME, Hanif W et al. Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia 2005; 48: 1084-7.
16. Sakai Y, Yamaji T, Tabata S et al. Relation of alcohol use and smoking to glucose tolerance status in Japanese men. Diabetes Res Clin Pract 2006; 73: 83-8.
17. Tabata S, Yin G, Ogawa S, Yamaguchi K, Mineshita M, Kono S. Genetic polymorphism of cholesterol 7α-hydroxylase (CYP7A1) and colorectal adenomas: Self Defense Forces Health Study. Cancer Sci 2006; 97: 406-10.
18. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
19. Nakano Y, Tajima S, Yoshimi A et.al. A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin. J Lipid Res 2006; 47: 1572-82.
20. Ainsworth BE, Haskell WL, Leon AS et al. Compendium of physical activities: Classification of energy costs of human physical activities. Med Sci Sports Exerc 1993; 25: 71-80.
21. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.
22. Vainio H, Bianchini F, eds. Weight Control and Physical Activity. IARC Handbooks of Caner Prevention, Vol. 6. Lyon: IARC Press, 2002; 85-95.
23. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res 2005; 11: 466-72.
24. Ishikawa M, Kitayama J, Yamauchi T et al. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci 2007; 98: 1120-7.
25. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
26. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380: 24-30.
27. Tilg H, Moschen AR. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-83.
28. Kaaks R, Toniolo P, Akhmedkhanov A et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000; 92: 1592-600.
29. Wei EK, Ma J, Pollak MN et al. C-Peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev 2006; 15: 750-5.
30. Schoen RE, Weissfeld JL, Kuller LH et al. Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. Gastroenterology 2005; 129: 464-75.
31. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer Inst 2005; 97: 1679-87.
32. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-89.
33. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002; 94: 972-80.
34. Basu R, Pajvani UB, Rizza RA, Scherer PE. Selective downregulation of the high-molecular-weight form of adiponectin in hyperinsulinemia and type 2 diabetes: Differential regulation from nondiabetic subjects. Diabetes 2007; 56: 2174-7.
35. Pischon T, Hotamisligil GS, Rimm EB. Adiponectin: Stability in plasma over 36.h and within-person variation over 1.year. Clin Chem 2003; 49: 650-2.